🔎 Trials Near Me

Hem › Akut myeloid leukemi › Wisconsin

Kliniska studier för Akut myeloid leukemi i Wisconsin

25 studier för Akut myeloid leukemi söker deltagare vid platser i Wisconsin.

Städer i Wisconsin

Officiell studietext (engelska)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Gundersen Lutheran Medical Center, La Crosse
RekryterarFas 2
Ålder 60 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • och 50 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Wisconsin, Milwaukee
RekryterarObservationsstudie
Ålder 0 till 38 · Alla kön · Uppdaterad 1 okt. 2026 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • Duluth Clinic Ashland, Ashland
  • och 6 fler
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 28 sep. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • Duluth Clinic Ashland, Ashland
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • och 41 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • Duluth Clinic Ashland, Ashland
  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • och 11 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Duluth Clinic Ashland, Ashland
  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
  • och 9 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • Duluth Clinic Ashland, Ashland
  • och 8 fler
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 22 sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
  • och 1 fler
RekryterarFas 3
6 Months – 21 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT04293562

A Study of BGB-11417 in Participants With Myeloid Malignancies

  • Medical College of Wisconsin, Milwaukee
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT04771130

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
RekryterarFas 3
Ålder 1 till 25 · Alla kön · Uppdaterad 4 sep. 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
RekryterarFas 1/2
Upp till ålder 22 · Alla kön · Uppdaterad 25 aug. 2026 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Wisconsin, Madison
  • Froedtert & Medical College of Wisconsin, Milwaukee
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Froedtert & Medical College Clinics, Milwaukee
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • Medical College of Wisconsin, Milwaukee
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT06656494

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Wisconsin - Madison, Madison
  • Children's Hospital of Wisconsin, Milwaukee
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 6 juli 2026 · NCT01351545

Ivosidenib as Post-HSCT Maintenance for AML

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 18 juni 2026 · NCT06707493

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  • University of Wisconsin Carbone Cancer Center, Madison
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 14 maj 2026 · NCT06222580

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Froedtert & Medical College of Wisconsin, Milwaukee
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 apr. 2026 · NCT04256317

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • University of Wisconsin Carbone Cancer Center, Madison
RekryterarFas 1
Upp till ålder 21 · Alla kön · Uppdaterad 22 apr. 2026 · NCT05101551

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Wisconsin Hospital and Clinics, Madison
  • Medical College of Wisconsin Cancer Center, Milwaukee
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 13 mars 2026 · NCT05735184

Venetoclax to Augment Epigenetic Modification and Chemotherapy

  • Children's Wisconsin, Milwaukee
RekryterarFas 1
Ålder 1 till 25 · Alla kön · Uppdaterad 12 jan. 2026 · NCT05317403

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • University of Wisconsin Carbone Cancer Center, Madison
RekryterarFas 1
7 Months – 21 Years · Alla kön · Uppdaterad 16 okt. 2025 · NCT02508038

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • University of Wisconsin Clinical Science Center, Madison
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2025 · NCT06501196

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • University of Wisconsin, Madison
RekryterarFriska volontärer välkomna
Ålder 18 till 120 · Alla kön · Uppdaterad 25 juli 2025 · NCT05237258

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.